first_imgThe shop at Bettys Café Tea Rooms in the centre of Ilkley is the second of the brand to be updated.All six Bettys Café Tea Room branches in Yorkshire will be undergoing improvements. The most recent completed redesign was that of Bettys Café Tea Rooms in St Helen’s Square, York.The Ilkley work used sustainably-sourced oak, cast bronze fittings and marble counter tops, in a style based on the Arts & Crafts movement, complementing the design of the café.There is now a tasting area to allow customers to sample Bettys Speciality Tea and Coffee, and a new chocolate counter offering a selection of 20 varieties of handcrafted chocolates. The shop will now also offer a wedding and celebration cake consultation service.Samantha Lawton, manager at Bettys Ilkley, said: “We are thrilled with the new-look shop.“We have been careful to keep the ‘Bettys feeling’ that we’re known and loved for, and our lighter and brighter shop area offers a much more engaging shopping experience for customers, with more room for browsing, sampling and demonstration of our craft skills.”last_img read more

first_img The snow tubing park at Wisp is a must-try with 2 conveyor carpets that do all work to get you up the hill while you can focus on the fun of going down.  The Mid-Atlantic’s only Mountain Coaster is next to the snow tubing park and operates year-round.  Be sure to bundle up as the Mountain Coaster can reach speeds up to 29 mph but don’t worry, riders can control the level of fun with hand brakes on the side of each coaster cart. Tucked away in the mountainous corner of Western Maryland, lies Wisp Resort.  With 33 slopes for skiing and snowboarding, all levels of skiers and snowboarders will find something fun and exciting.  The Learning Center at Sundown Village caters to first-time and beginner skiers and snowboarders by making the process as easy as possible with everything located in one place.  It’s also a unique place, made up of 8 50’ yurts, with 3 yurts dedicated to the adult learning center and 2 for the Wisp Kids learning program. Located just 14 miles off of I-68, Wisp is highly accessible to the Baltimore and DC Metro areas but the climate is worlds away from those cities.  Garrett County receives an average of 100” of snow annually and, during a typical winter, neighboring Deep Creek Lake is frozen solid enough to welcome ice fisherman and snowmobilers.center_img A bustling base area at Wisp offers the McHenry Lodge with various restaurants and bars, shopping outlets and a day skier area with 30’ high windows looking up at the slopes.  In addition to the various food courts on property, Wisp Resort offers two full-service restaurants with feature items that will please all palates, including vegetarian and gluten-free diets.  Take a look menus for Wispers Bar & Grill and DC’s Bar & Restaurant. Connected to the main building is The Lodge at Wisp, a ski-in/ski-out hotel that just got better – $3.7 million better!  Last year, a 3-year renovation project was completed, boasting renovation of 169 hotel rooms, a new entrance with porté cochere, waterfall, landscaping, firepits, new lobby and front desk, renovated meeting and function space with new audio visual equipment and a new fitness center.  Take a look at the lodging packages available with activities already built in. The Wisp Escape Games were added in 2017, which feature two distinctly different escape rooms.  A great family and team building activity to try after hitting the slopes all day. With all of these options, your family is bound to have a grand adventure at Wisp Resort – Maryland’s only four season destination for outdoor recreation.  last_img read more

first_img To achieve prepandemic vaccines, researchers would have to ascertain the right dose and dose interval, determine how long priming lasts, and solve the puzzle of measuring primed immunity. Further, regulatory authorities would have to determine the trial design that could deliver those answers, the public discussion that would be necessary for prepandemic vaccines to be accepted, and the safety data that would need to be gathered once the vaccines went into use (see Bibliography: Goodman 2007). A number of the studies that have shown adjuvants may be able to stretch the vaccine supply also demonstrated a secondary benefit: The formulas protected not only against the H5N1 flu strain on which they were based, but against other H5N1 strains as well, a phenomenon called cross-reactive protection (see Bibliography: Nicholson 2001, Stephenson 2005, Govorkova 2006, Hehme 2007, Hoffenbach 2007). Most recently, the GlaxoSmithKline-backed team that described an acceptable immune response after two adjuvanted 3.8-microgram (mcg) doses found that three fourths of their subjects were protected not only against the clade 1 Vietnam virus on which the vaccine was based, but against a drifted clade 2 virus from Indonesia as well (see Bibliography: Leroux-Roels 2007). “I think priming should be done, but I am not sure how it should be done,” said Dr. John Wood, principal scientist in the division of virology at the United Kingdom’s National Institute for Biological Standards and Control. “What we don’t know is how low you can go to actually prime people. It may be that you can go much lower than where we can detect antibody. That is a regulatory headache, because you have to demonstrate that you are doing something, but there is a potential there” (see Bibliography: Wood 2007: author interview). At the moment, however, the science is thin. Much of the support for priming has come from animal studies (see Bibliography: Lipatov 2005, Govorkova 2006, Kreijtz 2007) or via computer modeling (see Bibliography: Longini 2005, Ferguson 2006, Germann 2006). A few small studies in humans have shown promising results. In one, serum from 15 volunteers who received three doses over 16 months of an adjuvanted vaccine based on a 1997 H5N3 isolate showed significant antibody response against H5N1 strains isolated years later (see Bibliography: Stephenson 2005). In another, 37 participants who had been given a baculovirus-grown, clade 3 H5 vaccine in 1998 were boosted with a single dose of the unadjuvanted 90-mcg Sanofi vaccine in 2005, and showed much higher antibody responses than participants who had not been primed but received one or two doses of the 90-mcg vaccine (see Bibliography: Treanor 2007: Immune responses). And researchers at a conference earlier this year reported that some of the participants in the phase 3 trial of the 90-mcg Sanofi vaccine were boosted with a third dose 6 months after their second dose and showed a significant rise in antibody levels that lasted for 6 months (see Bibliography: Zangwill 2007). A tough ethical problemBut the next logical step—that if vaccines can be formulated without waiting for a pandemic, they could be administered before a pandemic began—is a much tougher one to take, and policy makers are approaching it with great caution. The scientific, logistical, and especially ethical questions raised by prepandemic vaccination are grave. “Extraordinary threats call for consideration of innovative strategies that, in less-threatening circumstances, might be dismissed,” Bruce Gellin and Ben Schwartz of the Department of Health and Human Services’ National Vaccine Program Office wrote 2 years ago. “Although it has been assumed that pandemic vaccine cannot be stockpiled or that vaccination cannot occur before the start of a pandemic, might these approaches actually be possible? . . . Would receipt of a vaccine prepared before the pandemic be effective in providing some protection or in priming recipients so a single subsequent dose of vaccine would be protective?” (see Bibliography: Schwartz 2005). The danger demonstrated by both those campaigns, of causing adverse events while protecting against a disease that might never arise, has been noted in World Health Organization (WHO) policies as well. “Possible high-risk shortcuts in response to a potential emergency would be difficult to justify prior to the actual occurrence of the emergency,” the agency said after the June 2006 meeting of its Global Advisory Committee on Vaccine Safety. “Effectiveness of pandemic vaccines will not be known before the pandemic and possibly only after it is over” (see Bibliography: WHO 2006: Global Advisory Committee on Vaccine Safety, 6-7 June 2006). The prime-boost strategyThe most likely and biologically plausible use of prepandemic vaccination would be as the first half of a “prime-boost” series. People would still be given the two doses of vaccine necessary to provoke immunity in a naïve individual. But the doses would be based on different vaccine strains—the first an early best guess, the second tuned to the pandemic strain—and could be given not weeks but months or years apart if the science supported it. Yet the potential benefits of prepandemic vaccination are so alluring that governments have begun gingerly to lay groundwork for its consideration, despite the obvious difficulties of putting the idea into practice. The findings are not completely understood, though researchers agree that they make biological sense. Adjuvants stimulate the immune system in some manner that is broader than and different from the body’s reaction to the antigen packaged with them. The discovery that adjuvanted flu vaccines may invoke cross-reactivity has generated tremendous excitement—because that could allow production of at least partially protective vaccines well in advance of a pandemic’s beginning. Part 1: Flu research: a legacy of neglectPart 2: Vaccine production capacity falls far shortPart 3: H5N1 poses major immunologic challengesPart 4: The promise and problems of adjuvantsPart 5: What role for prepandemic vaccination?Part 6: Looking to novel vaccine technologiesPart 7: Time for a vaccine ‘Manhattan Project’?Bibliography Hurdles are manySo many steps separate those early results from an agreed-upon policy that would allow for prepandemic vaccines—in an annual flu shot or stockpiled until the WHO declares a pandemic imminent—that it is unrealistic to expect them to be created any time soon. The scientific questions alone are significant and novel. Any vaccination that took place before a pandemic was detected would offer uncertain amounts of both benefit and risk. The vaccine might be cross-protective against a future pandemic—but the lag time to the pandemic’s emergence might be so long that the vaccination would seem pointless. As well, the vaccine might cause a greater-than-expected rate of adverse events, causing both direct harm to recipients and indirect damage to government credibility—results that would be particularly difficult to tolerate if vaccination proved unnecessary because the pandemic did not arrive. Those risks are not theoretical: They have been demonstrated in the United States twice in recent history, in the abortive 2002 smallpox vaccination campaign and the 1976 swine-flu campaign (see Bibliography: Kotalik 2005), which has haunted US flu decision-making ever since. Editor’s note: This is the fifth in a seven-part series investigating the prospects for development of vaccines to head off the threat of an influenza pandemic posed by the H5N1 avian influenza virus. The series puts promising advances in vaccine technology in perspective by illuminating the formidable barriers to producing large amounts of an effective and widely usable vaccine in a short time frame. Part 4 examined the possibility of using adjuvants to stretch the supply of pandemic vaccines and the regulatory barriers to that strategy. Recognizing those hurdles, the European Centre for Disease Prevention and Control said in August that while it welcomes the development of prepandemic vaccines, it would not support administering them until a WHO declaration of pandemic phase 5 or 6, meaning significant human-to-human transmission is occurring or a pandemic is under way (see Bibliography: ECDC 2007: “Pre-pandemic” vaccines might offer protection but uncertainties remain). The pandemic vaccine puzzle Oct 31, 2007 (CIDRAP News) – Experiments with vaccine adjuvants have raised some hope of removing one of the great stumbling blocks to pandemic influenza preparedness: the impossibility of making a vaccine that protects against a pandemic virus before that virus actually emerges. last_img read more

first_imgELLSWORTH — The Down East Family YMCA Dolphins posted their best-ever Maine Swimming International Invitational finish when they placed second at the meet in Saint John, N.B.DEFY took first place in 21 individual events and four relay events. The Dolphins also broke 24 team records in the meet, which was held July 13-15 and featured teams from New England and New Brunswick.Nineteen-year-old Talor Hamilton set records in the boys’ 50- and 100-meter butterflies, 50-meter freestyle and 100-meter backstroke He also earned a first-place finish in the 200-meter backstroke.Colin Aponte and Nick Partridge also set multiple records for DEFY in their respective age groups. Aponte, 12, did so in the 50-meter backstroke, freestyle and butterfly, and Partridge accomplished the feat in the 50- and 100-meter breaststrokes.This is placeholder textThis is placeholder textOther first-place finishers for the Dolphins were Sam Alvarado, Camden Holmes, Cooper Holmes, Richie Matthews, Ava Sealander and Hannah Wood.last_img read more

first_img Published on December 12, 2015 at 10:17 pm Related Stories Dougherty: Michael Gbinije, thriving or not, is tailor made for Syracuse Facebook Twitter Google+center_img Sam Blum (6-3)Syracuse 82, St. John’s 69New York’s College TeamThat’s always the question, isn’t it? Whose state is it? Last year it belonged to the Johnnies, but this isn’t the same Red Storm team. Syracuse reasserts itself in its home away from home in front of a partisan Orange crowd.Jesse Dougherty (6-3)Syracuse 77, St. John’s 55Driving through the stormSt. John’s has a lot of young talent, but it’s knee-deep in a rebuilding process and lost to Fordham (Fordham!) by 16 points on Dec. 2. The Red Storm also gave up 93 points in a win over Chaminade. St. John’s’ most recent result is a 48-44 win over a Niagara team that lost to Vermont by 18, Youngstown State by 18 … You get the point. Syracuse shouldn’t allow the Red Storm to even sniff a win in Madison Square Garden on Sunday, and anything less than a lopsided win would be disappointing for the Orange.Matt Schneidman (6-3)Syracuse 71, St. John’s 60Bright lightsAdvertisementThis is placeholder textFor Syracuse’s standout freshmen, Madison Square Garden is the biggest stage they’ll have played on yet. The Red Storm have had a less-than-stellar beginning to the season and Malachi Richardson and Tyler Lydon, two players who struggled in Syracuse’s back-to-back losses but got back on track against Colgate, will lead the Orange to a convincing victory. MSG is the platform for jumping up another peg as Syracuse tries to climb back into the Top 25. Commentslast_img read more

first_imgGhana slipped three places down on the latest FIFA ranking released for April on Thursday but moved up one place in Africa to occupy the fourth position on the continent.The Black Stars are now ranked the 38th best team in the world after moving up two places for the March edition.But the 2014 World Cup finalists moved one place up on the Africa ranking to fourth place.Ivory Coast remain the highest ranked African country and 21st in the world.The Elephants are followed by Egypt (24th) and Algeria (25th).Europe occupies the top three places after Portugal climbed third behind leaders Spain and Germany. They are followed by four South American sides in Colombia (4th, up 1), Uruguay (5th, up 1) and fierce rivals Argentina (down 3) and Brazil (up 3), who share sixth position.Only six matches were played over the past month.The majority of changes can be attributed to the devaluation of matches from previous years, most of which were FIFA World Cup qualifiers and now have a greatly reduced weighting.last_img read more